DNA-based Zika vaccine is safe and effective at inducing immune response

October 4, 2017
Credit: CC0 Public Domain

A new generation DNA-based Zika vaccine demonstrated both safety and ability to elicit an immune response against Zika in humans in a phase 1 clinical trial conducted through a partnership among the Perelman School of Medicine at the University of Pennsylvania, Inovio Pharmaceuticals, GeneOne Life Science, and The Wistar Institute. The research was published in the New England Journal of Medicine.

Zika virus is a mosquito-borne infection associated with and neurological complications in adults. In 2015 and 2016, Zika virus spread rapidly through Brazil, the Caribbean, and the southern United States. However, no approved or treatment is currently available. This is the first study to show that a DNA vaccine can produce an immune response against the virus with minimal adverse effects, opening the door to further trials to move this vaccine forward.

"Synthetic DNA vaccines are an ideal approach for emerging like Zika," said David B. Weiner, Ph.D., executive vice president of The Wistar Institute, director of Wistar's Vaccine & Immunotherapy Center, developer of the Zika vaccine and collaborating author on the study. "This of DNA vaccines can be designed and manufactured rapidly, they appear to be highly predictable for the generation of immunity in humans, have significant conceptual safety advantages, and they are more stable than most traditional vaccines, making them exceptionally practical to distribute during outbreaks, especially in regions where resources are limited and we need to be able to respond quickly to curb an emerging epidemic."

The GLS-5700 vaccine contains the synthetic DNA instructions for the host to learn how to mount an against a specific Zika virus antigen. Researchers enrolled 40 participants in the safety trial between August and September of 2016. Two groups of 20 participants received two different doses of the vaccine candidate intradermally at zero, four, and 12 weeks. Each dosage was followed by Cellectra delivery at the site, which generates small, directional electric currents into the skin to facilitate optimal vaccine uptake, production of the intended antigen, and immune responses.

Results showed that two weeks after the final dose 100 percent of study participants developed Zika-specific antibodies and 80 percent developed significant neutralizing antibodies against the virus. Importantly, serum from the study participants was able to protect immunocompromised mice from developing the disease after infection with Zika virus, indicating that the vaccine-induced antibodies can prevent infection in vivo. The vaccine was also well tolerated.

"Zika virus continues to be a threat to people living in the Americas and the Caribbean," said Pablo Tebas, M.D., professor of Infectious Diseases at the University of Pennsylvania and lead author on the study. "With these new results, we are one step closer to hopefully finding a way to prevent infection, which can cause serious birth defects and developmental delays in babies born to women who are infected with Zika."

Explore further: Potential Zika vaccine protects against pregnancy transmission and testicular damage

Related Stories

Potential Zika vaccine protects against pregnancy transmission and testicular damage

September 26, 2017
For the first time, a collaborative team led by The University of Texas Medical Branch at Galveston has shown that a potential Zika vaccine quickly can protect fetuses against infection as well as protect males against testicular ...

Translational research leads to potential Zika virus vaccine

May 10, 2017
Preclinical results of research by City College of New York scientists and TechnoVax, Inc. in animal models demonstrate favorable outcomes in developing a vaccine against the mosquito-borne Zika virus. The results were announced ...

Zika vaccine protects fetus against infection and birth defects

July 13, 2017
Immunizing female mice with a Zika vaccine can protect their developing fetus from infection and birth defects during pregnancy, according to new research from The University of Texas Medical Branch at Galveston. The findings ...

CDC shutters command center for Zika monitoring

October 3, 2017
With Zika waning in the Caribbean and South America, the Centers for Disease Control and Prevention announced on Friday that the federal agency was deactivating the command center for monitoring and coordinating emergency ...

Experimental Zika vaccine to begin human testing

June 20, 2016
An experimental vaccine for the Zika virus is due to begin human testing in coming weeks, after getting the green light from U.S. health officials.

DNA-based Zika vaccine showed protection from infection, brain damage and death

November 10, 2016
As the global spread of the Zika virus continues, efforts are underway to halt the disease's transmission. While no licensed therapies or vaccines to protect against the Zika virus are currently available, new research published ...

Recommended for you

New insights into herpes virus could inform vaccine development

October 18, 2017
A team of scientists has discovered new insights into the mechanisms of Epstein-Barr virus (EBV) infection, as well as two antibodies that block the virus' entry into cells. The findings, published in Proceedings of the National ...

Pair of discoveries illuminate new paths to flu and anthrax treatments

October 17, 2017
Two recent studies led by biologists at the University of California San Diego have set the research groundwork for new avenues to treat influenza and anthrax poisoning.

Portable 3-D scanner assesses patients with elephantiasis

October 17, 2017
An estimated 120 million people worldwide are infected with lymphatic filariasis, a parasitic, mosquito-borne disease that can cause major swelling and deformity of the legs, a condition known as elephantiasis. Health-care ...

New tools to combat kidney fibrosis

October 16, 2017
Interstitial fibrosis – excessive tissue scarring – contributes to chronic kidney disease, which is increasing in prevalence in the United States.

How hepatitis C hides in the body

October 13, 2017
The Hepatitis C (HCV) virus is a sly enemy to have in one's body. Not only does it manage to make itself invisible to the immune system by breaking down communication between the immune cells, it also builds secret virus ...

Largest study yet of malaria in Africa shows historical rates of infection

October 12, 2017
(Medical Xpress)—A team of researchers with members from the Kenya Medical Research Institute, the University of Oxford and the University of KwaZulu-Natal has conducted the largest-ever study of the history of malaria ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.